Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Return on Capital Employed (2022 - 2025)

Prime Medicine (PRME) has disclosed Return on Capital Employed for 4 consecutive years, with 0.64% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed rose 9.0% year-over-year to 0.64%, compared with a TTM value of 0.64% through Dec 2025, up 9.0%, and an annual FY2025 reading of 0.74%, up 24.0% over the prior year.
  • Return on Capital Employed was 0.64% for Q4 2025 at Prime Medicine, up from 0.69% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.45% in Q4 2022 and bottomed at 1.28% in Q4 2023.
  • Average Return on Capital Employed over 4 years is 0.79%, with a median of 0.75% recorded in 2025.
  • The sharpest move saw Return on Capital Employed tumbled -83bps in 2023, then surged 55bps in 2024.
  • Year by year, Return on Capital Employed stood at 0.45% in 2022, then tumbled by -187bps to 1.28% in 2023, then soared by 43bps to 0.73% in 2024, then grew by 13bps to 0.64% in 2025.
  • Business Quant data shows Return on Capital Employed for PRME at 0.64% in Q4 2025, 0.69% in Q3 2025, and 0.76% in Q2 2025.